Managing immune checkpoint-blocking antibody side effects.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

• Publication date

  2015-05-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.14694/EdBook_AM.2015.35.76PMID 25993145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.

  2015cited by this paper
• Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• Ipilimumab in patients with melanoma and autoimmune disease

  2014cited by this paper
• Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

  2014cited by this paper
• Opportunistic infections in patients treated with immunotherapy for cancer

  2014cited by this paper
• Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).

  2014cited by this paper
• Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

  2014cited by this paper
• Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

  2014cited by this paper
• Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

  2014cited by this paper
• Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient

  2014cited by this paper
• Ipilimumab in patients with cancer and the management of dermatologic adverse events.

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Kidney injuries related to ipilimumab

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease

  2014cited by this paper
• Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

  2014cited by this paper
• Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

  2014cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• Neurological immune-related adverse events of ipilimumab

  2013cited by this paper
• Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.

  2013cited by this paper
• Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Ipilimumab associated hepatitis: imaging and clinicopathologic findings

  2013cited by this paper
• The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

  2013cited by this paper
• Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells

  2013cited by this paper
• Ipilimumab-induced acute severe colitis treated by infliximab.

  2013cited by this paper
• Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis

  2013cited by this paper
• BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

  2013cited by this paper
• Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma

  2013cited by this paper
• Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.

  2013cited by this paper
• Endocrine side effects induced by immune checkpoint inhibitors.

  2013cited by this paper
• Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Vemurafenib sensitivity skin reaction after ipilimumab.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Ipilimumab-induced immune-related renal failure--a case report.

  2012cited by this paper
• Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

  2012cited by this paper
• Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.

  2012cited by this paper
• Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus

  2012cited by this paper
• Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease.

  2011cited by this paper
• Hemophilia A induced by ipilimumab.

  2011cited by this paper
• The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

  2010cited by this paper
• Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

  2010cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

  2009cited by this paper
• Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

  2009cited by this paper
• Anti-CTLA4 antibody-induced lupus nephritis.

  2009cited by this paper
• Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.

  2009cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

  2009cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2009cited by this paper
• Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

  2009cited by this paper
• Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis

  2009cited by this paper
• Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

  2009cited by this paper
• Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient

  2008cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

  2005cited by this paper
• Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.

  2004cited by this paper
• Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis1

  2001cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes

  1998cited by this paper

• Immunotherapy-Related Adverse Events and Clinical Outcomes in Adult Solid-Tumor Patients Admitted to an Onco-Hospitalist Medicine Service

  2025cites this paper
• Two Japanese Cases of Breast Cancer That Developed Pembrolizumab-Induced Adrenal Insufficiency and Literature Review

  2025cites this paper
• Non-coding RNAs in gastric cancer immunotherapy: mechanisms and clinical implications

  2025cites this paper
• Navigating skin toxicity in the era of immunotherapy

  2025cites this paper
• Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report

  2025cites this paper
• Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment

  2025cites this paper
• Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee

  2025cites this paper
• Effect of antiemetic corticosteroids on the development of immune-related adverse events caused by chemoimmunotherapy: a multicenter retrospective study

  2025cites this paper
• Molecular pathways of radiation-induced lung damage: Effects of X-ray and Anti-PD-1 combination in a murine model.

  2025cites this paper
• Contemporary Management of Immune Checkpoint Inhibitor-related Adverse Events

  2025cites this paper
• A Case Report of Pembrolizumab-Induced Allergic Hepatitis

  2024cites this paper
• A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

  2024cites this paper
• Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.

  2024cites this paper
• Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

  2024cites this paper
• Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient

  2024cites this paper
• Enhanced Efficacy of a TLR3 Agonist Delivered by Cowpea Chlorotic Mottle Virus Nanoparticles

  2024cites this paper
• Sulconazole inhibits PD-1 expression in immune cells and cancer cells malignant phenotype through NF-κB and calcium activity repression

  2024cites this paper
• Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy

  2024cites this paper
• Monoclonal antibodies in neuro-ophthalmology

  2024cites this paper
• Association of Nutritional Indices With Adverse Effects and Time-to-Treatment-Failure in Triple Therapy for Lung Cancer

  2024cites this paper
• SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study

  2024cites this paper
• Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies

  2024cites this paper
• Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report

  2023cites this paper
• Genetic lesions and targeted therapy in Hodgkin lymphoma

  2023cites this paper
• Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity

  2023cites this paper
• Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study

  2023cites this paper
• Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study

  2023cites this paper
• Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

  2023cites this paper
• Pituitary and adrenal disorders induced by immune checkpoint inhibitors.

  2023cites this paper
• Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review

  2023cites this paper
• Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist

  2023cites this paper
• Cutaneous manifestations associated with immune checkpoint inhibitors

  2023cites this paper
• Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer

  2023cites this paper
• How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.

  2023cites this paper
• Association between PD‐1 inhibitor‐related adverse events and frailty assessed by frailty index in lung cancer patients

  2023cites this paper
• PD-1/PD-L1 AXIS INHIBITORS AS PROMISING STRATEGY FOR MANAGEMENT OF HEPATOCELLULAR CARCINOMA: EXPECTATIONS, BOUNDARIES AND PITFALLS

  2023cites this paper
• Pituitary hypoadrenocorticism and hypothyroidism after immunochemotherapy followed by salvage surgery for lung cancer: a case report

  2023cites this paper
• Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review

  2023cites this paper
• Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience

  2023cites this paper
• Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events

  2023cites this paper
• Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

  2023cites this paper
• Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study

  2023cites this paper
• Research Progress of Immune Checkpoint Inhibitors in Melanoma

  2023cites this paper
• Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer

  2023cites this paper
• Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer

  2023cites this paper
• In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

  2022cites this paper
• The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study

  2022cites this paper
• Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

  2022cites this paper
• Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.

  2022cites this paper
• Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings

  2022cites this paper
• Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors

  2022cites this paper
• Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer

  2022cites this paper
• Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review

  2022cites this paper
• A Seven-Autophagy-Related Long Non-Coding RNA Signature Can Accurately Predict the Prognosis of Patients with Renal Cell Carcinoma

  2022cites this paper
• Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis

  2022cites this paper
• Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect.

  2022cites this paper
• Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis

  2022cites this paper
• Thyroid Dysfunction in Non‐Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta‐Analysis

  2022cites this paper
• Targeting protein kinases benefits cancer immunotherapy.

  2022cites this paper
• Plasmid DNA cationic non-viral vector complexes induce cytotoxicity-associated PD-L1 expression up-regulation in cancer cells in vitro.

  2022cites this paper
• PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?

  2021cites this paper
• Renal Toxicity.

  2021cites this paper
• Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases

  2021influential citation
• Melanoma: An Update on Systemic Therapies.

  2021cites this paper
• Systematic review: disease activity indices for immune checkpoint inhibitor‐associated enterocolitis

  2021cites this paper
• Immune Checkpoint Blockade and Skin Toxicity Pathogenesis.

  2021cites this paper
• The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma

  2021cites this paper
• European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

  2021cites this paper
• Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma

  2021cites this paper
• Immune Checkpoint Inhibitor Induced Colitis: A Nationwide Population-Based Study.

  2021cites this paper
• Imunoterapia como tratamento de câncer e o papel da enfermagem

  2021cites this paper
• Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review

  2021cites this paper
• A case of lichenoid oral mucositis associated with nivolumab therapy

  2021cites this paper
• Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes

  2021cites this paper
• 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究

  2021cites this paper
• Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options

  2021cites this paper
• Rethinking the management of immune checkpoint inhibitor‐related adrenal insufficiency in cancer patients during the COVID‐19 pandemic

  2021cites this paper
• A Simple Reversed Phase High Performance Liquid Chromatography Method for the Estimation of Related Substances, Assay of Cabozantinib and Nivolumab and its Application to Dissolution Studies

  2021cites this paper
• A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?

  2021cites this paper
• Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World Data

  2021cites this paper
• Toxicities of Novel Antineoplastic Therapies

  2021cites this paper
• Targeted Therapies in Cancer Treatment

  2021cites this paper
• Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review

  2021cites this paper
• Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

  2021cites this paper
• Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report.

  2021influential citation
• Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer

  2021cites this paper
• Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust in vivo anti‐tumour efficacy

  2021cites this paper
• Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia

  2021cites this paper
• Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach

  2021cites this paper
• Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities

  2021cites this paper
• Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review

  2021cites this paper
• CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department

  2021cites this paper
• “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

  2021cites this paper
• Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis

  2021cites this paper
• Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management

  2021cites this paper
• Prodrug-Based Versatile Nanomedicine with Simultaneous Physical and Physiological Tumor Penetration for Enhanced Cancer Chemo-Immunotherapy.

  2021cites this paper
• Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)

  2020influential citation
• Highly Enhanced Antitumor Immunity by Three Barrelled Strategy of L-arginine Promoted Nanovaccine and Gene-mediated PD-L1 Blockade.

  2020cites this paper
• Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature

  2020cites this paper
• New Insights into the Role of Sphingolipid Metabolism in Melanoma

  2020cites this paper